circPTP4A2‐miR‐330‐5p‐PDK2 Signaling Facilitates In Vivo Survival of HuMSCs on SF‐SIS Scaffolds and Improves the Repair of Damaged Endometrium
article
OA: hybrid
CC0
⤵ 2 in-corpus citations
AI-generated summary
HuMSCs seeded on SF-SIS scaffolds promote endometrial repair by stabilizing mitochondrial metabolism via the circPTP4A2-miR-330-5p-PDK2 signaling pathway.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Background: Human umbilical cord mesenchymal stem cells- (HuMSCs-) based therapy has shown promising results in the treatment of intrauterine adhesions (IUA). In this study, we aimed to construct a HuMSCs-seeded silk fibroin small-intestinal submucosa (SF-SIS) scaffold and evaluate its ability to repair the damaged endometrium in an IUA mouse model. Methods: To identify the functional effect of HuMSCs-SF-SIS scaffolds on the repair of damaged endometrium, a mouse IUA model was established. Uterine morphology and fibrosis were evaluated by hematoxylin-eosin staining and Masson staining. CircRNA sequencing, real-time PCR, and RNA fluorescence in situ hybridization were used to screen and verify the potential circRNAs involved in the repair of damaged endometrium by HuMSCs. Real-time integrated cellular measurement of oxygen consumption rate was performed using the Seahorse XF24 Extracellular Flux Analyzer. The potential downstream miRNAs and proteins of circRNAs were analyzed by dual-luciferase reporter assay and western blot. Results: HuMSCs-SF-SIS not only increased the number of glands but also reduced the ulcer area in the IUA model. circPTP4A2 was elevated in the HuMSCs seeded on the SF-SIS scaffolds and was targeted by miR-330-5p-PDK2. It also stabilized the mitochondrial metabolism of HuMSCs. Moreover, miR-330-5p was found to inhibit PDK2 expression through the 3' UTR target region. A rescue experiment further showed that circPTP4A2-miR-330-5p-PDK2 signaling was critical to HuMSCs-SF-SIS in decreasing the fibrosis area and increasing the number of glands in the IUA model. Conclusion: We demonstrated that circPTP4A2 was elevated in HuMSCs-seeded on SF-SIS scaffolds and stabilized the mitochondrial metabolism through miR-330-5p-PDK2 signaling, which contributes to endometrial repair progression. These findings demonstrate that HuMSCs-seeded SF-SIS scaffolds have potential for the treatment of IUA.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
- Endometriosis: pathogenesis and treatment 2013
- Endometrial Stem Cell Markers: Current Concepts and Unresolved Questions 2018
- circPTP4A2‐miR‐330‐5p‐PDK2 Signaling Facilitates In Vivo Survival of HuMSCs on SF‐SIS Scaffolds and Improves the Repair of Damaged Endometrium 2022
- circPTP4A2-miR-330-5p-PDK2 Signaling Facilitates In Vivo Survival of HuMSCs on SF-SIS Scaffolds and Improves The Repair of Damaged Endometrium 2021
Cited by (2)
References (46)
- circPTP4A2‐miR‐330‐5p‐PDK2 Signaling Facilitates In Vivo Survival of HuMSCs on SF‐SIS Scaffolds and Improves the Repair of Damaged Endometrium via openalex
- circPTP4A2-miR-330-5p-PDK2 Signaling Facilitates In Vivo Survival of HuMSCs on SF-SIS Scaffolds and Improves The Repair of Damaged Endometrium via openalex
- Endometrial Stem Cell Markers: Current Concepts and Unresolved Questions via openalex
- Endometriosis: pathogenesis and treatment via openalex
- doi:10.1007/s13238-017-0385-7 via openalex
- doi:10.1016/j.repbio.2016.10.002 via openalex
- doi:10.1016/j.actbio.2019.05.012 via openalex
- doi:10.1186/s13287-019-1179-z via openalex
- doi:10.1038/cdd.2017.51 via openalex
- doi:10.1093/humupd/dmy034 via openalex
- doi:10.1016/j.biomaterials.2014.11.028 via openalex
- doi:10.3904/kjim.2015.30.5.580 via openalex
- doi:10.1089/scd.2015.0117 via openalex
- doi:10.1016/j.stem.2017.07.011 via openalex
- doi:10.1038/ncomms9472 via openalex
- doi:10.1186/s13287-019-1332-8 via openalex
- doi:10.4103/0974-1208.82360 via openalex
- doi:10.1016/j.tig.2016.03.002 via openalex
- doi:10.1186/s12943-020-01246-x via openalex
- doi:10.1186/s13287-020-01642-6 via openalex
- doi:10.1186/s13287-020-01662-2 via openalex
- doi:10.1186/s13287-020-01610-0 via openalex
- doi:10.1016/j.jconrel.2019.12.007 via openalex
- doi:10.1016/j.msec.2020.111641 via openalex
- doi:10.1016/j.msec.2019.110538 via openalex
- doi:10.1016/j.bioactmat.2020.11.023 via openalex
- doi:10.1093/humrep/deaa289 via openalex
- doi:10.7150/thno.41225 via openalex
- doi:10.1007/s13402-020-00503-x via openalex
- doi:10.1126/sciadv.aba6357 via openalex
- doi:10.1186/s13046-019-1376-8 via openalex
- doi:10.1093/humupd/dmt045 via openalex
- doi:10.1186/s13045-018-0554-z via openalex
- doi:10.7150/ijbs.57915 via openalex
- doi:10.1016/j.biomaterials.2015.02.092 via openalex
- doi:10.1016/j.semcdb.2016.02.011 via openalex
- doi:10.1039/d0bm00448k via openalex
- doi:10.1016/j.biomaterials.2018.03.027 via openalex
- doi:10.1016/j.pharmthera.2018.01.010 via openalex
- doi:10.3390/ph14070618 via openalex
- doi:10.1002/sctm.18-0297 via openalex
- doi:10.1093/humupd/dmv051 via openalex
- doi:10.1002/smll.201906273 via openalex
- doi:10.1186/s13287-018-0904-3 via openalex
- doi:10.1039/c9tb00530g via openalex
- doi:10.1002/sctm.18-0105 via openalex
Cited by (2)
Source provenance
- openalex
- last seen: 2026-05-11T06:18:49.075943+00:00
License: CC0
· commercial use OK